

1 **Serotype-Specific Epidemiological Patterns of Inapparent versus Symptomatic Primary**
2 **Dengue Virus Infections: A 17-year cohort study in Nicaragua**

3
4 Sandra Bos PhD^{1*}, Jose Victor Zambrana MPH^{2,3*}, Elias Duarte BS¹, Aaron L. Graber BA¹, Julia
5 Huffaker BS¹, Carlos Montenegro BS², Lakshmanane Premkumar PhD⁴, Pr. Aubree Gordon
6 PhD³, Guillermina Kuan MD^{2,5}, Angel Balmaseda MD^{2,6}, Pr. Eva Harris PhD^{1#}

7
8 ¹Division of Infectious Diseases and Vaccinology, School of Public Health, University of California,
9 Berkeley, Berkeley, CA

10 ²Sustainable Sciences Institute, Managua, Nicaragua

11 ³Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, MI

12 ⁴Department of Microbiology and Immunology, University of North Carolina School of Medicine,
13 Chapel Hill, NC

14 ⁵Centro de Salud Sócrates Flores Vivas, Ministerio de Salud, Managua, Nicaragua

15 ⁶Laboratorio Nacional de Virología, Centro Nacional de Diagnóstico y Referencia, Ministerio de
16 Salud, Managua, Nicaragua

17

18 *These authors contributed equally to this work.

19 #Corresponding author: eharris@berkeley.edu

20 **Research in context**

21 **Evidence before this study**

22 We conducted a search in PubMed for studies published up to February 2024. Keywords included
23 "dengue virus" and "DENV" in combination with "inapparent infections", "asymptomatic
24 infections", "primary infections by serotype", "Fol by serotype", "force of infection", "force of
25 infection by serotype", and identified a significant gap in the current understanding of dengue
26 epidemiology. Despite acknowledging the high prevalence of inapparent DENV infections in
27 endemic regions, previous research has focused primarily on symptomatic infections, potentially
28 biasing our understanding of the DENV epidemiological landscape and hindering our capacity to
29 determine the complete disease spectrum of the different DENV serotypes. While cross-sectional
30 studies have provided preliminary insights into this gap, there is a need for more comprehensive
31 and detailed serotype-specific insights to evaluate the epidemiological impact of inapparent
32 infections. The lack of comprehensive characterization of inapparent infections reflects
33 methodological challenges, particularly the need for prospective cohort studies designed to
34 capture and accurately serotype these infections. Moreover, the reliance on labor-intensive and
35 low-throughput antibody neutralization assays for serotyping, despite their accuracy, has
36 constrained high-throughput analysis required for large-scale epidemiological studies.

37 **Added value of this study**

38 Our study, spanning 17 years of prospective cohort data in Nicaragua, addresses this bottleneck
39 in dengue research by providing a detailed examination of primary inapparent infections. The
40 introduction of a novel envelope domain III (EDIII) multiplex microsphere-based assay for DENV
41 serotyping represents a significant methodological advance, offering an efficient, scalable
42 alternative for large epidemiological studies. A key contribution of our study is the intricate pattern
43 of serotype distribution among inapparent infections. In contrast to the serotype predominance
44 observed in symptomatic infections, inapparent infections exhibit a complex landscape with co-
45 circulation of multiple DENV serotypes, including serotypes undetected in symptomatic
46 surveillance in multiple years. Our systematic documentation of the entire disease spectrum

47 provides unprecedented insights into the serotype-specific disease burden in primary infection,
48 including the proportion of symptomatic versus inapparent infection and its temporal variations,
49 thus providing a more complete picture of DENV epidemiology than has been available to date.
50 Notably, we demonstrate striking differences in disease severity by serotype, with DENV3
51 infections being significantly more symptomatic and more severe compared to DENV1 and
52 DENV2, the latter displaying the highest rate of inapparent infection.

53 **Implications of all the available evidence**

54 Our research challenges prior assumptions by demonstrating that inapparent and symptomatic
55 primary DENV infections present distinct epidemiological profiles, revealing that the
56 epidemiological footprint of DENV is broader and more nuanced than previously recognized
57 through symptomatic cases alone. These findings underscore the utility for continuous and
58 comprehensive surveillance systems that capture both symptomatic and inapparent infections to
59 accurately assess the epidemiological burden of DENV and inform public health interventions.
60 Additionally, they provide critical insight for enhancing the accuracy of predictive DENV
61 transmission modeling. Furthermore, the marked differences in infection outcomes by serotype
62 emphasize the need for serotype-informed public health strategies. This nuanced understanding
63 is pivotal for the crafting of targeted interventions, vaccine development and vaccination
64 strategies, and efficient resource allocation, ultimately contributing to the global effort to mitigate
65 the impact of dengue.

66 **Abstract**

67 **Background.** Dengue is the most prevalent mosquito-borne viral disease and a major public
68 health problem worldwide. Most primary infections with the four dengue virus serotypes (DENV1-
69 4) are inapparent; nonetheless, whether the distribution of symptomatic versus inapparent
70 infections by serotype varies remains unknown. Here, we present (1) the evaluation of a multiplex
71 DENV1-4 envelope domain III multiplex microsphere-based assay (EDIII-MMBA) to serotype
72 inapparent primary infections and (2) its application leveraging 17 years of prospective sample
73 collection from the Nicaraguan Pediatric Dengue Cohort Study (PDCS).

74 **Methods.** First, we evaluated the performance of the EDIII-MMBA with samples characterized by
75 RT-PCR or focus reduction neutralization test. Next, we analyzed 46% (N=574) of total inapparent
76 primary DENV infections in the PDCS with the EDIII-MMBA to evaluate the epidemiology of
77 inapparent infections. Remaining infections were inferred using stochastic imputation, taking year
78 and neighborhood into account. Infection incidence and percentage of inapparent, symptomatic,
79 and severe infections were analyzed by serotype.

80 **Findings.** The EDIII-MMBA demonstrated excellent overall accuracy (100%, 95·8-100%) for
81 serotyping symptomatic and inapparent primary DENV infections when evaluated against gold-
82 standard serotyping methods. We found that a significant majority of primary infections were
83 inapparent, with DENV3 exhibiting the highest likelihood of symptomatic and severe primary
84 infections (Pooled OR compared to DENV1 = 2·13, 95% CI 1·28-3·56, and 6·75, 2·01-22·62,
85 respectively), whereas DENV2 was similar to DENV1 in both analyses. Significant within- and
86 between-year variation in serotype distribution between symptomatic and inapparent infections
87 and circulation of serotypes undetected in symptomatic cases were observed in multiple years.

88 **Interpretation.** Our study indicates that case surveillance skews the perceived epidemiological
89 footprint of DENV. We reveal a more complex and intricate pattern of serotype distribution in
90 inapparent infections. The significant differences in infection outcomes by serotype emphasizes
91 the need for vaccines with balanced immunogenicity and efficacy across serotypes.

92 **Funding**

93 NIH/NIAID P01AI106695, U01AI153416

94 **Introduction**

95 Dengue, caused by the four dengue virus serotypes (DENV1-4), is the most prevalent mosquito-
96 borne viral disease in humans and a significant global health threat.¹ Infection outcomes range
97 from inapparent/subclinical infection to severe, potentially fatal disease. The global dissemination
98 of DENV, alongside the co-circulation of its serotypes, has increased both the incidence and
99 severity of the disease in recent decades.^{1,2} This epidemiological shift emphasizes the need for a
100 comprehensive understanding of the circulation and interactions among the different serotypes
101 and their implications for disease outcomes.

102
103 Infection with one of the four antigenically related DENV serotypes leads to the production of type-
104 specific antibodies as well as cross-reactive antibodies that can bind to other serotypes. These
105 antibodies can either protect or increase the risk of subsequent symptomatic or severe DENV
106 infection in both natural infections and vaccines.³⁻⁵ In this context, one factor that can influence
107 clinical outcome is the infecting serotype.^{5,6} Further, an association between the order of DENV
108 serotype infection and clinical outcome has been reported,⁶ suggesting that the initial infecting
109 serotype may modulate infection outcomes.^{5,7,8}

110
111 While the majority of primary DENV infections are inapparent, they significantly contribute to the
112 force of infection, transmission, and overall epidemiological burden.^{9,10} However, accurately
113 assessing this burden, understanding the complete disease spectrum associated with each
114 serotype, and predicting the risk of severe disease outcomes upon subsequent infection have
115 been challenging due to the lack of characterization of inapparent infections. This knowledge gap
116 stems from methodological limitations, particularly the need for prospective cohort studies
117 designed to capture and serotype inapparent infection, compounded by the low-throughput nature
118 of neutralization assays that are used to identify serotype in inapparent infections. Consequently,
119 prior research has predominantly focused on symptomatic infections, potentially skewing our
120 understanding of the DENV epidemiological landscape.

121

122 To address this bottleneck in dengue research, we leveraged 17 years of prospective sample
123 collection from participants enrolled in our pediatric cohort in Nicaragua and demonstrated the
124 hidden contribution of inapparent infection to both the overall and serotype-specific DENV burden
125 in Nicaragua between 2004 and 2021. To achieve this, we used an envelope domain III multiplex
126 microsphere-based assay (EDIII-MMBA), previously validated to differentiate DENV and Zika
127 virus (ZIKV) infections and determine the number of prior DENV infections, to serotype inapparent
128 DENV infection.¹¹ We then examined the distribution of DENV serotypes in inapparent versus
129 symptomatic primary infections, the proportion of inapparent infections per serotype, and their
130 temporal dynamics in the PDCS, together revealing the full disease spectrum associated with
131 primary DENV infection by serotype.

132 **Methods**

133 **Study design and participants**

134 In this study, we first evaluated the performance of the EDIII-MMBA to serotype primary DENV
135 infections and subsequently used it to characterize the serotype of inapparent primary infections
136 and evaluate the epidemiological and clinical landscape of primary DENV infections in Nicaragua.
137 To do so, we leveraged serum samples collected from 2004 to 2021 from our ongoing Pediatric
138 Dengue Cohort Study (PDCS),¹² which has followed ~4,000 active participants aged 2-17 years
139 old since 2004. The PDCS is conducted at the Sócrates Flores Vivas Health Center located in
140 District 2 of Managua, Nicaragua. Dengue cases are detected by enhanced passive surveillance,
141 and healthy samples are collected annually in March-April, which allows the detection of
142 inapparent infections. Ethics statements, description of the PDCS and participants, case
143 definitions, and severity classifications are described in the Supplementary Appendix.¹² In this
144 study, we included DENV-naïve participants at enrollment (N=5931) and followed them until they
145 experienced a primary DENV infection (N=1626). Participants with DENV or ZIKV immunity at
146 enrollment were excluded (N=5824).

147 **Procedures**

148 A primary DENV infection was defined among individuals who entered the cohort DENV-naïve
149 and ZIKV-naïve as measured by DENV iELISA and ZIKV NS1 blockade-of-binding ELISA and
150 who maintained this status until their seroconversion to DENV. Symptomatic DENV infections
151 were confirmed by detection of DENV RNA by RT-PCR and/or virus isolation in the acute phase
152 sample and/or seroconversion detected in paired acute- and convalescent-phase samples by
153 DENV IgM capture ELISA or iELISA. Inapparent primary DENV infections were detected by
154 seroconversion between 2 consecutive annual samples in the absence of any documented
155 dengue case, according to the case definition, in the intervening year. Disease severity of
156 symptomatic DENV infections was classified according to the 2009 WHO Dengue Guidelines.¹⁵
157 Procedures, case definitions, and assays are explained in detail in the Supplementary Appendix.

158
159 The "gold standard" to serotype inapparent infections is the DENV1-4 neutralization assay, which
160 is both time- and sample-intensive. To address these limitations, we evaluated the performance
161 of a multiplex assay containing EDIII of DENV1-4 and ZIKV conjugated to avidin-coated
162 microspheres via an Avi-Tag,¹¹ the EDIII-MMBA, to serotype primary infections. The EDIII-MMBA
163 was evaluated against RT-PCR and focus reduction neutralization test (FRNT) using 156 late
164 convalescent samples from the annual sample collection (3-9 months post-infection) that
165 constituted the evaluation set (86 inapparent infections and 70 symptomatic infections selected
166 by convenience sampling). See Supplementary Appendix for details. Of the 1244 inapparent
167 primary infections that occurred from 2004 to 2021 as captured by the DENV iELISA, 574 (46%)
168 were processed by the EDIII-MMBA assay to study the epidemiology of primary DENV infection
169 in the PDCS. Selection of this subset for screening by the EDIII-MMBA was performed by random
170 selection of 40% of primary DENV-infected individuals each year, and when there were less than
171 20 inapparent primary infections, 100% were selected, restricted to those with serum/plasma
172 available from the following annual sample collection (3-9 months post-infection). This sample
173 selection yielded samples from 478 individuals (87%); to improve precision, we included 76
174 inapparent samples (13%; excluding 10 ZIKV infections) from the evaluation subset.

175 **Outcomes and endpoints**

176 Outcomes included inapparent, symptomatic, severe, and overall primary DENV infections as
177 defined in the Procedures section and Supplementary Appendix. Our primary endpoints included
178 the ratio of symptomatic versus inapparent and severe versus non-severe DENV infections by
179 serotype. Our secondary analyses include a year-by-year analysis of the relative distribution of
180 DENV serotypes in inapparent versus symptomatic DENV infections, the percent of symptomatic
181 DENV infections by serotype over time by serotype, and the overall infection incidence by
182 serotype over time.

183 **Statistical methods**

184 The accuracy of the EDIII-MMBA assay to serotype primary DENV infections was evaluated by
185 comparing it to gold standards: RT-PCR (symptomatic) and FRNT (inapparent). Sensitivity,
186 specificity, and accuracy, calculated as the sum of the true positives and true negatives divided
187 by the total number of samples evaluated, were calculated for each serotype (DENV1-4) and Zika
188 virus (ZIKV) across all test combinations. We calculated 95% confidence intervals (95% CI) using
189 the exact binomial method for all the performance measures.

190
191 To determine population-level infection parameters over time by DENV serotype, including
192 percent infected among the DENV-naïve population and percent of severe, symptomatic and
193 inapparent primary infections, we addressed missingness of serotype in both inapparent and
194 symptomatic primary DENV infections by employing multiple imputation with stochastic
195 Multivariate Imputation by Chained Equations (MICE). A polytomous logistic regression model,
196 incorporating epidemic year and neighborhood as predictors, was used to impute missing
197 serotypes. We ran independent imputation models for inapparent and symptomatic infections,
198 running 1000 simulations with 10 iterations for both models. The resulting imputed datasets were
199 merged for analysis, pooling all results across simulations. To understand the temporal trends of
200 infected individuals by outcome (symptomatic vs. inapparent) for each serotype, we plotted the

201 pooled counts and percentages across imputations over time. Additionally, we calculated the
202 relative distribution of serotypes by outcomes over time.

203

204 For our primary endpoints, we analyzed the ratio of symptomatic and severe infections out of the
205 total infections specific to each serotype using separate logistic regression models by
206 symptomatic and severe infections, adjusting by serotype and controlling by epidemic year. As
207 secondary endpoints, we analyzed the within-year relative distribution of serotypes by inapparent
208 and symptomatic infections by employing Fisher's exact test to both serotyped and imputed data.
209 Additionally, we analyzed changes in the percent symptomatic infections by DENV serotype over
210 time by applying logistic regression models measuring the likelihood of symptomatic infection by
211 epidemic year and stratifying by serotype. Finally, we analyzed the infection incidence proportion
212 by serotype by applying intercept-only logistic regression models measuring the likelihood of
213 infection stratifying by each serotype. A conceptual framework of our assumptions about the
214 relationship between the variables used in our analyses is shown in the Supplemental Appendix.
215 A validation of our final imputation model and various sensitivity analyses on our primary
216 endpoints were performed (Supplementary Appendix). To account for the imputed data, we
217 pooled the analyses across simulations using Rubin's rule to obtain estimates and 95% CI for the
218 model coefficients. All statistical analyses and data imputation were executed in R (version 4.3.2),
219 utilizing the 'mice' package (version 3.16.0).

220 **Role of the funding source**

221 The sponsor of the study had no role in study design, data collection, data analysis, data
222 interpretation, or writing of the report. The corresponding author had full access to all the data in
223 the study and had final responsibility for the decision to submit for publication.

224 **Results**

225 In this study, we analyzed primary DENV infection data from the PDCS from 2004 to 2021,
226 involving a median of 1536 (IQR = 1425-1861) DENV-naïve participants followed annually (Table

227 S1). Notably, this period includes the ZIKV epidemic in 2016, which significantly dampened DENV
228 circulation in Nicaragua in 2016-2018. We first evaluated the count and incidence proportion of
229 primary infections (figure 1A-B). Over the 17-year period, we observed significant year-to-year
230 fluctuations in the number of primary infections, ranging from 6 in 2018 to 289 in 2019, with a
231 median annual incidence proportion of 4% (IQR = 1-9%) within the study population (Table S1).
232 Prior to the emergence of ZIKV, a median of 105 (IQR = 72-124) primary infections was recorded
233 annually, which dropped to 9 (IQR = 7-12) from 2016 to 2018, before a significant resurgence of
234 DENV primary infections in 2019 (N=287). Out of the 1626 total primary infections we studied,
235 382 were symptomatic, while 1244 were inapparent. We found that a median of 77% (IQR = 68-
236 86) of primary infections were inapparent, although this percentage varied significantly across
237 epidemic years (figure 1C).

238
239 Considering the predominance of inapparent primary infections, serotyping these infections is
240 critical to evaluate the epidemiological burden and virulence associated with each serotype. Thus,
241 we evaluated the performance of the EDIII-MMBA to serotype primary infections. Exceptional
242 performance (100% sensitivity, specificity, and accuracy) was observed when evaluated against
243 both RT-PCR and FRNT for DENV1-4 and ZIKV (Table 1). Concordance of EDIII-MMBA values
244 with RT-PCR and FRNT is shown in figure 2.

245
246 The EDIII-MMBA was conducted on 574 out of 1244 (46%) primary inapparent infections recorded
247 in the PDCS between 2004 and 2021, of which 425 (74%) were successfully serotyped. Twenty-
248 five infections (4%) were excluded due to either invalid serotyping (N=21) (see Supplementary
249 Appendix) or ZIKV infection (N=14). Anti-EDIII antibody levels below the detection limit (1:50)
250 were observed in 114 (19%) samples. This discrepancy might be due to the difference in the type
251 of antibody measured (anti-EDIII IgG), compared to the iELISA used initially to detect infection
252 (total Ig primarily directed towards anti-pr and anti-E fusion loop antibodies).³ Using the total
253 number of samples screened, we performed an analysis of the capacity of the EDIII-MMBA to
254 provide valid serotyping of primary infection samples as detected by iELISA (n=564). Including

255 the 114 samples with no detectable anti-EDIII antibodies and the 21 samples with invalid
256 serotyping, the sensitivity of the EDIII-MMBA was 76·5%, compared to 95·4% when only
257 participants with anti-EDIII antibodies were included (n=460). The breakdown of serotyped and
258 non-serotyped infections, along with a flowchart illustrating the screening and serotyping process,
259 are provided in Table S2 and figure S1. Missing serotype data on the remaining inapparent and
260 symptomatic infections were imputed using the results of EDIII-MMBA and RT-PCR, respectively
261 (figure S2). The convergence of our final imputation models was assessed using trace plots,
262 which indicated robust performance with no discernible trends in the final iterations (figures S3-
263 5). Our final imputation models were validated and showed high agreement with the
264 experimentally serotyped data, with an overall accuracy of 0·89 (0·85-0·92) for symptomatic
265 infection and 0·78 (0·74-0·82) for inapparent infection (Table S3-6).

266
267 Throughout the study period, DENV serotypes 1, 2, and 3 were the dominant serotypes,
268 representing 98% of total primary infections, reflecting the serotypes circulating in the country.¹³
269 In contrast, DENV4 circulation was very low and was exclusively detected in inapparent infections.
270 The analysis of primary infections revealed distinct serotype distributions, with significant
271 differences observed between the proportions of symptomatic versus inapparent infections
272 caused by each serotype every year (figure 3A). For instance, in 2004, DENV1 was the only
273 serotype detected in symptomatic cases, whereas all four serotypes circulated within the
274 inapparent infection fraction. During the 2008-2010 period, DENV3 was dominant in symptomatic
275 cases but exhibited lower relative prevalence within the inapparent fraction. Significant within-
276 year variations in serotype distribution were observed between the symptomatic and inapparent
277 infection fractions, particularly in 2004 (p 0·011), 2007 (p 0·021), 2008 (p 0·0025), and 2009 (p
278 0·005) (figure 3A, Table S7). These variations and temporal dynamics were consistent across
279 experimentally serotyped and imputed datasets (figure 3A and figure S2C).

280
281 Subsequent stratification of the cumulative incidence proportions of inapparent and symptomatic
282 infections by serotype (figure 3B) further accentuates the pattern observed initially: whereas

283 symptomatic infections tend to be dominated by a single serotype, the DENV landscape unveiled
284 by inapparent infections is more complex, with co-circulation of multiple DENV serotypes,
285 including serotypes undetected in symptomatic surveillance, in multiple years.

286
287 DENV2 demonstrated the most extended circulation period and the highest overall incidence in
288 our study compared to DENV1 and DENV3 (Table S8). Nevertheless, analyzing the cumulative
289 annual incidence proportion of primary symptomatic and inapparent infections per serotype
290 highlighted dynamic shifts in the dominance of DENV serotypes. While DENV2 dominated the
291 initial years of the study, this dominance transitioned to DENV3 in 2009-2010 and subsequently
292 shifted to DENV1 during the 2012-2013 period, before DENV2 resurgence in 2019 (figure 4A,
293 Table S9). A marked change in DENV2 incidence proportion was particularly notable in 2019,
294 with 17% (95% CI 15–19%) of the naïve population experiencing primary DENV2 infections
295 compared to only 4% (95% CI 3–5%) in 2006 (figure 4A, figure S6, Table S9). The incidence
296 proportion of primary DENV3 infections was particularly high between 2008 and 2011, reaching
297 up to 7% (95% CI 6–9%) of the naïve population at its peak whereas for DENV1, incidence peaked
298 in 2012 (6%, 95% CI 5–7%).

299
300 Analyzing the proportion of symptomatic infections among total infections per serotype over time
301 revealed considerable yearly fluctuations. Excluding years when no symptomatic infections were
302 found and years with <10 primary infections per serotype, the proportion of DENV1 symptomatic
303 infections among DENV1 total infections ranged from 7% (95% CI 1–36%) in 2006 to a peak of
304 40% (95% CI 31%–49%) in 2012; DENV2 ranged from 6% (95% CI 2–16%) in 2006 to 29%
305 (95%CI 24–35%) in 2019, and DENV3 ranged from 26% (95% CI 15–40%) in 2011 to 44% (95%
306 CI 22–69%) in 2014 (figure 4B, Table S9). Notably, at the serotype level, years of the most intense
307 outbreaks coincided with the highest proportion of symptomatic infections for all serotypes. To
308 evaluate differences in virulence over time by serotype, we also report the values in pooled odds
309 ratio form (Table S10-12).

310

311 Further investigation into the disease spectrum of primary infections underscored stark
312 differences by serotype. Analyzing symptomatic versus inapparent and severe versus non-severe
313 outcomes, DENV3 demonstrated significantly higher likelihood of symptomatic (Pooled Odds
314 Ratio [POR] = 2·13, 95% CI 1·28–3·56) and severe infections (POR = 6·75, 95% CI 2·01–22·62),
315 as evidenced by POR compared to DENV1 adjusting by epidemic year, whereas DENV2 did not
316 show significant differences in either analysis compared to DENV1 (figure 5A-B). Such results
317 were consistent across all the sensitivity analyses performed (Table S13).

318
319 Lastly, we summarized the spectrum of disease observed in primary infections caused by the
320 three major DENV serotypes that circulated in Nicaragua between 2004 and 2021 by analyzing
321 the frequency of inapparent, symptomatic, and severe DENV infections classified according to
322 the WHO guidelines from 2009 (figure 5C). Although we found that a significant majority of primary
323 infections remained inapparent, symptomatic infection was observed in 23·2% (19·2-27·8%),
324 20·1% (17·4-23·2%) and 36·1% (31·1-41·4%) of DENV1, DENV2, and DENV3 infection
325 respectively. Among total primary infections, severe disease was observed in 2·5% (1·3-4·6%) of
326 DENV1, 1·4% (0·8-2·6%) of DENV2, and 7·4% (5·1-10·6%) of DENV3 infections further
327 highlighting the variability in infection outcomes associated with each serotype (Table S14).

328 **Discussion**

329 Our study provides novel insights into serotype-specific epidemiological patterns and disease
330 outcomes of primary DENV infections in Nicaragua by revealing the hidden contribution of
331 inapparent infections. The EDIII multiplex microsphere-based assay has been previously
332 evaluated to detect any prior ZIKV or prior DENV infection, showing a sensitivity of 94·9% and
333 100%, and a specificity of 97·8% and 98·5%, respectively.¹¹ Here we expanded and evaluated its
334 use for serotyping primary DENV infections, which demonstrated high performance when
335 evaluated against the gold standard FRNT and RT-PCR assays. This significant methodological
336 advancement offers a scalable and efficient alternative to the labor-intensive neutralization assays
337 traditionally used to serotype infection. Compared to neutralization assays such as the FRNT, the

338 microsphere-based assays are easier to standardize across laboratories and can be performed
339 without the need for handling infectious materials under BSL2 conditions.

340

341 The majority of primary infections within our cohort were inapparent (76%), aligning with existing
342 literature that suggests a high prevalence of inapparent and subclinical infection across dengue-
343 endemic regions.¹⁴⁻¹⁷ However, the proportion of inapparent infections greatly fluctuates across
344 years. The characterization of these infections allowed us to examine the serotype-specific
345 proportion of primary inapparent infections and their temporal variability for the first time.
346 Importantly, our study shows that while a single serotype often dominates symptomatic primary
347 infections in any given period, the landscape of inapparent infections in Nicaragua is far more
348 complex, revealing the co-circulation of multiple serotypes and serotype circulation undetected in
349 symptomatic cases across multiple years. This observation suggests that the epidemiological
350 footprint of DENV is broader and more nuanced than what is captured by monitoring symptomatic
351 cases alone, whenever there is co-circulation of serotypes or hyperendemicity. This finding
352 underscores the utility for continuous and comprehensive surveillance systems that capture both
353 symptomatic and inapparent infections to accurately assess the epidemiological burden of DENV
354 and inform public health interventions.

355

356 Temporal variations in the incidence and proportion of symptomatic primary infections further
357 highlighted the evolving landscape of dengue in Nicaragua. Notably, we observed an increase in
358 virulence of DENV1 over time, with more symptomatic primary infection in 2012 compared to
359 2004-2006. Furthermore, DENV2 infectivity surged in 2019, with 17% of the DENV-naïve
360 population experiencing primary infections versus 5% in 2006. These changes could potentially
361 be due to strain differences over time. Although our study does not directly link these observations
362 to specific viral genetic variation, this hypothesis is supported by prior studies showing lineage
363 shifts in DENV1 and DENV2 within our cohort (figure S7).^{13,18,19} Further, the level of population-
364 level susceptibility to different serotypes, as well as changes in host or environmental factors may
365 also influence infection dynamics and outcomes. For instance, the extensive circulation of ZIKV

366 in 2016 may have enhanced the DENV2 epidemic in 2019.^{5,6,20–22} Additionally, increases in
367 comorbidities (e.g., the rise in prevalence of obesity) in our cohort might also influence dengue
368 disease burden.²³ Finally, dengue cohort studies have reported large fluctuations in the yearly
369 proportion of symptomatic infections and have determined that the predominant circulating
370 serotype is one of the main factors driving this fluctuation.^{8,24}

371
372 By dissecting the full disease spectrum associated with primary DENV infection, our study
373 revealed stark serotype-specific differences in infection outcome. Specifically, our finding
374 supports and extends existing literature by demonstrating that DENV3 primary infections were not
375 only significantly more severe,^{25–27} but also significantly more symptomatic compared to DENV1
376 and DENV2. For instance, a study of schoolchildren in Thailand found that schools with high
377 DENV3 circulation were associated with lower detection of inapparent infections.²⁴ Another study
378 in Nicaragua found that among symptomatic infections, more severe primary infections are
379 caused by DENV3 than by DENV1 or DENV2.²⁷ Here, we expand on these results by taking the
380 full spectrum of primary infections into consideration, including inapparent infections.
381 Furthermore, our study shows that the low rate of symptomatic primary DENV2 infections in
382 Nicaragua is not due to a scarcity of primary infections but rather due to a high rate of inapparent
383 infections. Also, it is important to note that while severe dengue is more prevalent during
384 secondary infections, it also occurs in primary infections, particularly with DENV3 and DENV1.^{27–}
385 ³⁰ Substantial morbidity and mortality can be attributed to primary infections, for example, ≥50%
386 of severe cases and fatalities in a study in India³¹ and 23% of hospitalized dengue patients in a
387 study in Mexico.³² Here, we also found a sizable amount of severe infections among primary
388 cases, being the highest for DENV3. All together, these studies show that primary infections
389 contribute significantly to disease burden. Thus, safe and effective vaccines for DENV-naïve
390 individuals are warranted.

391
392 This study has several strengths. First, we expanded the use of a new simpler, high-throughput
393 method for serotyping inapparent primary infections. Second, we analyzed 17 years of data based
394 on a robust cohort study design that enables investigation of temporal dynamics of multiple DENV

395 serotypes in a consistent, single setting with a large sample size. The study design captures
396 inapparent, mild, and severe DENV infections, offering a comprehensive view of the disease
397 burden that refines our understanding of DENV epidemiology. Further, while serotyping
398 inapparent primary infections is not unique to our study, most studies are cross-sectional^{33–35}
399 reporting “crude” seroprevalence of a given serotype. Here we report the evolution of the
400 incidence of primary infection by serotype over time.

401
402 However, our study has some limitations, including minimal DENV4 circulation during the study
403 timeframe. Nonetheless, among primary infections, we predict that DENV4 has a similar spectrum
404 of symptomatic versus inapparent infection outcome compared to DENV2 as evidenced in the
405 literature.²⁵ The emergence of ZIKV might have impacted the DENV epidemiology in Nicaragua,
406 which would affect our findings after 2016, especially for DENV2. Yet, when restricting our
407 analyses from 2004-2015, our findings were similar. As our findings reflect the serotype
408 distribution in Nicaragua, the generalizability of our findings may be somewhat limited by the
409 regional focus and the genotype of local DENV strains (Table S15), which may have distinct
410 virulence and infectivity. Nevertheless, we believe that our findings provide a robust rationale for
411 future research in different settings to assess the epidemiology of other DENV genotypes and
412 broader implications of our findings. The random selection of inapparent samples for EDIII
413 serotyping likely mitigated selection bias, providing an unbiased estimate of serotype distribution
414 among inapparent infections, but our imputation model assumes such data to be missing at
415 random, dependent on time and space; deviations from this assumption could bias our findings.
416 Our final imputation models were valid, except for DENV4, which accounted for only 2% of the
417 inapparent infections. Our results remained robust when excluding DENV4 infections from our
418 imputation models and across other sensitivity analyses. Finally, although we adjusted for age
419 and sex in the imputation and main endpoint models, we cannot rule out residual confounding.

420
421 In summary, using a high throughput serotyping method to analyze inapparent primary DENV
422 infections in a cohort over 17 years, our study enriches the epidemiological data landscape with

423 unprecedented detail. Our findings reveal significant differences in the epidemiological profile of
424 symptomatic and inapparent DENV infections and show serotype-specific patterns and disease
425 spectra. The stark differences in disease outcome by serotype, particularly the symptomatic and
426 severe nature of DENV3 infections versus others, highlight the need for balanced and effective
427 vaccines across serotypes that provide protection even for those without prior DENV exposure.
428 These insights are also important in refining existing models of DENV transmission and mark an
429 advancement in our understanding of the serotype-specific risks of infection outcome, which
430 allows us to better predict outbreaks and hospital admission, understand DENV transmission
431 dynamics, and inform vaccine development.

432 **Acknowledgements**

433 We thank the study personnel at Centro de Salud Sócrates Flores Vivas, the Nicaraguan National
434 Virology Laboratory, the Hospital Infantil Manuel de Jesús Rivera, and the Sustainable Sciences
435 Institute. We are particularly grateful to the study participants and their families. This work was
436 supported by the National Institute of Allergy and Infectious Diseases/National Institutes of Health
437 (NIAID/NIH) via grants P01AI106695 (E.H.) and U01AI153416 (E.H.). The PDCS study was
438 supported by NIAID/NIH grants P01AI106695 (E.H.), U01AI153416 (E.H.), U19AI118610 (E.H.),
439 and R01AI099631 (A.B.), the Pediatric Dengue Vaccine Initiative grant VE-1 (E.H.) from the Bill
440 and Melinda Gates Foundation, and NIH subcontract HHSN2722001000026C (E.H.).

441 **Authors contributions**

442 Conceptualization: SB, JVZ, EH
443 Methodology: SB, JVZ, PL
444 Investigation: SB, JVZ, EMD, JH, ALG, CM
445 Visualization: SB, JVZ
446 Funding acquisition: AB, EH
447 Project administration: GK, AG, AB, EH
448 Manuscript writing – first draft: SB, JVZ, EH

449 Manuscript writing – review and editing: All authors

450 Access and data verification – SB, JVZ, EH

451 Manuscript submission decision - SB, JVZ, EH

452 **Competing interests**

453 Aubree Gordon has received institutional payments from Flu Lab and Open Philanthropy,
454 personal honoraria from Hope College and La Jolla Institute of Immunology, payments for expert
455 testimony, travel support from the Gates Foundation and NIH, and has an advisory role with
456 Janssen Pharmaceuticals. Other authors report no conflict of interest.

457 **Data availability**

458 All relevant data supporting the findings of this study are included within the manuscript or the
459 supplementary appendix. Normalized EDIII-MMBA values from our evaluation set are accessible
460 in the supplementary material “Transformed_EDIII-MMBA_Values.” We kindly request that
461 researchers who utilize the data provided for their own studies acknowledge this by citing this
462 paper.

463 Additional datasets generated and/or analyzed during the current study are available upon
464 reasonable request, following the protocol approved by the Institutional Review Board (IRB) for
465 the Pediatric Dengue Cohort Study. Researchers who wish to access the additional data are
466 encouraged to submit a formal request to Dr. Eva Harris or the Committee for the Protection of
467 Human Subjects at the University of California, Berkeley. In accordance with ethical guidelines
468 and to ensure the proper use of the data, all requests will be reviewed and approved on a case-
469 by-case basis. The associated code for this study is available for reference on Zenodo (doi:
470 10.5281/zenodo.12349676).

471 References

- 472 1 Yang X, Quam MBM, Zhang T, Sang S. Global burden for dengue and the evolving
473 pattern in the past 30 years. *J Travel Med* 2021; **28**. DOI:10.1093/jtm/taab146.
- 474 2 Lee SY, Shih H-I, Lo W-C, Lu T-H, Chien Y-W. Discrepancies in dengue burden
475 estimates: a comparative analysis of reported cases and global burden of disease
476 study, 2010-2019. *J Travel Med* 2024; **31**. DOI:10.1093/jtm/taae069.
- 477 3 Katzelnick LC, Gresh L, Halloran ME, *et al*. Antibody-dependent enhancement of
478 severe dengue disease in humans. *Science* 2017; **358**: 929–32.
- 479 4 Sabchareon A, Wallace D, Sirivichayakul C, *et al*. Protective efficacy of the
480 recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai
481 schoolchildren: a randomised, controlled phase 2b trial. *Lancet* 2012; **380**: 1559–
482 67.
- 483 5 Katzelnick LC, Narvaez C, Arguello S, *et al*. Zika virus infection enhances future
484 risk of severe dengue disease. *Science* 2020; **369**: 1123–8.
- 485 6 Zambrana JV, Hasund CM, Aogo RA, *et al*. Primary exposure to Zika virus is linked
486 with increased risk of symptomatic dengue virus infection with serotypes 2, 3, and
487 4, but not 1. *Sci Transl Med* 2024; **16**: eadn2199.
- 488 7 Bhoomiboonchoo P, Nisalak A, Chansatiporn N, *et al*. Sequential dengue virus
489 infections detected in active and passive surveillance programs in Thailand, 1994-
490 2010. *BMC Public Health* 2015; **15**: 250.
- 491 8 Tsang TK, Ghebremariam SL, Gresh L, *et al*. Effects of infection history on dengue
492 virus infection and pathogenicity. *Nat Commun* 2019; **10**: 1246.
- 493 9 Ten Bosch QA, Clapham HE, Lambrechts L, *et al*. Contributions from the silent
494 majority dominate dengue virus transmission. *PLoS Pathog* 2018; **14**: e1006965.
- 495 10 Duong V, Lambrechts L, Paul RE, *et al*. Asymptomatic humans transmit dengue
496 virus to mosquitoes. *Proc Natl Acad Sci U S A* 2015; **112**: 14688–93.
- 497 11 Dahora L, Castillo IN, Medina FA, *et al*. Flavivirus Serologic Surveillance: Multiplex
498 Sample-Sparing Assay for Detecting Type-Specific Antibodies to Zika and Dengue
499 Viruses. 2023; published online April 7. DOI:10.2139/ssrn.4411430.
- 500 12 Kuan G, Gordon A, Avilés W, *et al*. The Nicaraguan pediatric dengue cohort study:
501 study design, methods, use of information technology, and extension to other
502 infectious diseases. *Am J Epidemiol* 2009; **170**: 120–9.
- 503 13 Cerpas C, Vásquez G, Moreira H, *et al*. Introduction of New Dengue Virus Lineages
504 of Multiple Serotypes after COVID-19 Pandemic, Nicaragua, 2022. *Emerg Infect*
505 *Dis* 2024; **30**: 1203–13.

- 506 14 Endy TP, Chunsuttiwat S, Nisalak A, *et al.* Epidemiology of inapparent and
507 symptomatic acute dengue virus infection: a prospective study of primary school
508 children in Kamphaeng Phet, Thailand. *Am J Epidemiol* 2002; **156**: 40–51.
- 509 15 Morrison AC, Minnick SL, Rocha C, *et al.* Epidemiology of dengue virus in Iquitos,
510 Peru 1999 to 2005: interepidemic and epidemic patterns of transmission. *PLoS*
511 *Negl Trop Dis* 2010; **4**: e670.
- 512 16 Asish PR, Dasgupta S, Rachel G, Bagepally BS, Girish Kumar CP. Global
513 prevalence of asymptomatic dengue infections - a systematic review and meta-
514 analysis. *Int J Infect Dis* 2023; **134**: 292–8.
- 515 17 Tissera H, Amarasinghe A, De Silva AD, *et al.* Burden of dengue infection and
516 disease in a pediatric cohort in urban Sri Lanka. *Am J Trop Med Hyg* 2014; **91**:
517 132–7.
- 518 18 Thongsripong P, Edgerton SV, Bos S, *et al.* Phylodynamics of dengue virus 2 in
519 Nicaragua leading up to the 2019 epidemic reveals a role for lineage turnover. *BMC*
520 *Ecol Evol* 2023; **23**: 58.
- 521 19 Edgerton SV, Thongsripong P, Wang C, *et al.* Evolution and epidemiologic
522 dynamics of dengue virus in Nicaragua during the emergence of chikungunya and
523 Zika viruses. *Infect Genet Evol* 2021; **92**: 104680.
- 524 20 Ribeiro GS, Hamer GL, Diallo M, Kitron U, Ko AI, Weaver SC. Influence of herd
525 immunity in the cyclical nature of arboviruses. *Curr Opin Virol* 2020; **40**: 1–10.
- 526 21 Pinotti F, Giovanetti M, de Lima MM, *et al.* Shifting patterns of dengue three years
527 after Zika virus emergence in Brazil. *Nat Commun* 2024; **15**: 632.
- 528 22 Estofolete CF, Versiani AF, Dourado FS, *et al.* Influence of previous Zika virus
529 infection on acute dengue episode. *PLoS Negl Trop Dis* 2023; **17**: e0011710.
- 530 23 Mercado-Hernandez R, Myers R, Carillo FB, *et al.* Obesity is associated with
531 increased pediatric dengue virus infection and disease: A 9-year cohort study in
532 Managua, Nicaragua. medRxiv. 2024; DOI: 2024.04.02.24305219.
- 533 24 Endy TP, Anderson KB, Nisalak A, *et al.* Determinants of inapparent and
534 symptomatic dengue infection in a prospective study of primary school children in
535 Kamphaeng Phet, Thailand. *PLoS Negl Trop Dis* 2011; **5**: e975.
- 536 25 Soo K-M, Khalid B, Ching S-M, Chee H-Y. Meta-Analysis of Dengue Severity
537 during Infection by Different Dengue Virus Serotypes in Primary and Secondary
538 Infections. *PLoS One* 2016; **11**: e0154760.
- 539 26 Cordeiro MT, Silva AM, Brito CAA, *et al.* Characterization of a dengue patient
540 cohort in Recife, Brazil. *Am J Trop Med Hyg* 2007; **77**: 1128–34.

- 541 27 Narvaez F, Montenegro C, Juarez JG, *et al.* Dengue severity by serotype in 19
542 years of pediatric clinical studies in Nicaragua. *medRxiv* 2024; published online Feb
543 13. DOI:10.1101/2024.02.11.24302393.
- 544 28 Nisalak A, Endy TP, Nimmannitya S, *et al.* Serotype-specific dengue virus
545 circulation and dengue disease in Bangkok, Thailand from 1973 to 1999. *Am J Trop*
546 *Med Hyg* 2003; **68**: 191–202.
- 547 29 Balmaseda A, Hammond SN, Pérez L, *et al.* Serotype-specific differences in clinical
548 manifestations of dengue. *Am J Trop Med Hyg* 2006; **74**: 449–56.
- 549 30 Harris E, Videa E, Pérez L, *et al.* Clinical, epidemiologic, and virologic features of
550 dengue in the 1998 epidemic in Nicaragua. *Am J Trop Med Hyg* 2000; **63**: 5–11.
- 551 31 Aggarwal C, Ahmed H, Sharma P, *et al.* Severe disease during both primary and
552 secondary dengue virus infections in pediatric populations. *Nat Med* 2024;
553 published online Feb 6. DOI:10.1038/s41591-024-02798-x.
- 554 32 Annan E, Treviño J, Zhao B, Rodriguez-Morales AJ, Haque U. Direct and indirect
555 effects of age on dengue severity: The mediating role of secondary infection. *PLoS*
556 *Negl Trop Dis* 2023; **17**: e0011537.
- 557 33 Sasmono RT, Taurel A-F, Prayitno A, *et al.* Dengue virus serotype distribution
558 based on serological evidence in pediatric urban population in Indonesia. *PLoS*
559 *Negl Trop Dis* 2018; **12**: e0006616.
- 560 34 Alagarasu K, Tomar S, Patil J, *et al.* Seroprevalence of dengue virus infection in
561 Pune City in India, 2019: A decadal change. *J Infect Public Health* 2023; **16**: 1830–
562 6.
- 563 35 Limothai U, Tachaboon S, Dinhuizen J, *et al.* Dengue pre-vaccination screening test
564 evaluation for the use of dengue vaccine in an endemic area. *PLoS One* 2021; **16**:
565 e0257182.

Figure 1




Figure 1. Overall symptomatic and inapparent DENV infections in the PDCS study from 2004 to 2021. (A) Yearly counts of DENV primary infections by symptomatic or inapparent status, as indicated. **(B)** Yearly cumulative incidence proportion of primary inapparent and symptomatic DENV infections. **(C)** Yearly percent of inapparent primary DENV infections. The pink shaded area in 2016 is the period when ZIKV circulated in the PDCS. The gray area in panel B covers the pooled incidence proportions of overall primary DENV infections by serotype. Dashed line in panel C is the yearly average of inapparent primary DENV infections across years, and gray area represents the confidence interval.

Figure 2




Figure 2. Concordance of relative EDIII-MMBA values from participants with primary DENV infection with values from RT-PCR and neutralization assay. (A) Symptomatic primary DENV infections confirmed by RT-PCR, and **(B)** inapparent primary DENV infections were confirmed by FRNT. Within the heatmaps, each cell indicates the Mean Fluorescence Intensity (MFI). MFI values per participant were transformed by dividing the MFI of each EDIII antigen by the highest MFI observed in the set. Adjacent to each heatmap, dendrograms display the hierarchical clustering of individuals based on Euclidean distances calculated for the normalized MFI values. On the right of the dendrograms, a color-coded column classifies individuals according to the "gold standard" assay results, providing a reference for true infection status.

Figure 3




Figure 3. Serotype distribution in primary symptomatic and inapparent infections by serotype from 2004 to 2021 in the PDCS. (A) Pooled relative distribution of DENV serotypes circulating yearly in inapparent and symptomatic primary DENV infections across multiple imputations. Transparency was added in years with infection count <30. The gray panel shows the total incidence of primary DENV infections. **(B)** Temporal dynamics of the percent of primary DENV infections by infection outcome (shown in upper and lower panels) and serotype across imputations. The gray area covers the pooled incidence proportions of overall primary DENV infections by infection outcome. p-values: *, $p < 0.05$; **, $p < 0.01$; ***, $p < 0.001$.

Figure 4



Figure 4. Temporal dynamics of symptomatic, inapparent, and overall primary DENV infections by serotype from 2004 to 2021 in the PDCS. (A) Pooled percent of primary DENV infections by infection outcome and serotype, as indicated in left, middle, and right panels across imputations. The gray area covers the pooled incidence proportions of overall primary DENV infections by serotype. **(B)** Proportion of symptomatic primary DENV infection by serotype (indicated in left, middle, and right panels). This analysis excludes years when no symptomatic infections or <10 primary infections were reported. This is the result of the pooled predicted marginal probabilities of disease given infection from logistic regressions adjusting for year, compared to reference years (dashed line) of the most intense outbreak (DENV1: 2012, DENV2: 2019, DENV3: 2009).

Figure 5




Figure 5. Spectrum of disease of primary DENV infections. (A) Pooled counts of symptomatic, overall, and crude percent of symptomatic primary DENV infections by DENV serotype, and pooled odds ratios (OR) adjusting by year showing the association between dengue case and serotype among primary DENV infections. (B) Pooled counts of severe, overall, and crude percent of severe primary DENV infections by DENV serotype, and pooled odds ratios (OR) adjusting by year showing the association between dengue case and serotype among primary DENV infections. (C) Spectrum of infection outcome and disease according to the 2009 classification as the crude pooled percentages of primary DENV infections.

Table 1. EDIII-MMBA performance

	DENV1	DENV2	DENV3	DENV4	ZIKV
RT-PCR vs EDIII-MMBA					
N	70	70	70	70	70
N by characteristic	TP ¹ = 16 FP ² = 0 FN ³ = 0 TN ⁴ = 54	TP = 13 FP = 0 FN = 0 TN = 57	TP = 20 FP = 0 FN = 0 TN = 50	TP = 6 FP = 0 FN = 0 TN = 64	TP = 15 FP = 0 FN = 0 TN = 55
Gold standard positive	16	13	20	6	15
Gold standard negative	54	57	50	64	55
Sensitivity	100 (79.4 - 100)	100 (75.3 - 100)	100 (83.2 - 100)	100 (54.1 - 100)	100 (78.2 - 100)
Specificity	100 (93.4 - 100)	100 (93.7 - 100)	100 (92.9 - 100)	100 (94.4 - 100)	100 (93.5 - 100)
Diagnostic accuracy	100 (94.9 - 100)	100 (94.9 - 100)	100 (94.9 - 100)	100 (94.9 - 100)	100 (94.9 - 100)
FRNT vs EDIII-MMBA					
N	86	86	86	-	86
N by characteristic	TP ¹ = 38 FP ² = 0 FN ³ = 0 TN ⁴ = 48	TP = 19 FP = 0 FN = 0 TN = 67	TP = 19 FP = 0 FN = 0 TN = 67	- - - -	TP = 10 FP = 0 FN = 0 TN = 76
Gold standard positive	38	19	19	-	10
Gold standard negative	48	67	67	-	76
Sensitivity	100 (90.7 - 100)	100 (82.4 - 100)	100 (82.4 - 100)	-	100 (69.2 - 100)
Specificity	100 (92.6 - 100)	100 (94.6 - 100)	100 (94.6 - 100)	-	100 (95.3 - 100)
Diagnostic accuracy	100 (95.8 - 100)	100 (95.8 - 100)	100 (95.8 - 100)	-	100 (95.8 - 100)

¹TP: True positive ; ²FP: False positive ; ³FN: False Negative ; ⁴TN: True Negative.